AZT Stock Overview
A life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ArcticZymes Technologies ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 16.30 |
| 52 Week High | NOK 27.00 |
| 52 Week Low | NOK 12.34 |
| Beta | 0.75 |
| 1 Month Change | 8.67% |
| 3 Month Change | 16.43% |
| 1 Year Change | -31.80% |
| 3 Year Change | -76.88% |
| 5 Year Change | -32.92% |
| Change since IPO | -34.80% |
Recent News & Updates
Recent updates
ArcticZymes Technologies ASA's (OB:AZT) 33% Share Price Surge Not Quite Adding Up
Mar 11
ArcticZymes Technologies ASA's (OB:AZT) Intrinsic Value Is Potentially 43% Above Its Share Price
Feb 15
Transition To Solution Provider Will Accelerate Market Penetration By Late 2025
Jan 20 ArcticZymes is shifting from raw materials to solutions, aiming for revenue growth through closer customer interactions and market penetration by late 2025.Take Care Before Jumping Onto ArcticZymes Technologies ASA (OB:AZT) Even Though It's 25% Cheaper
Nov 28Analysts Are More Bearish On ArcticZymes Technologies ASA (OB:AZT) Than They Used To Be
Nov 12ArcticZymes Technologies ASA Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Nov 09The Price Is Right For ArcticZymes Technologies ASA (OB:AZT) Even After Diving 28%
Aug 31ArcticZymes Technologies' (OB:AZT) Solid Earnings May Rest On Weak Foundations
Aug 30ArcticZymes Technologies ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 25Earnings Miss: ArcticZymes Technologies ASA Missed EPS By 17% And Analysts Are Revising Their Forecasts
May 12ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Feb 08ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 04Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
Feb 02ArcticZymes Technologies ASA's (OB:AZT) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Apr 29Downgrade: Here's How This Analyst Sees ArcticZymes Technologies ASA (OB:AZT) Performing In The Near Term
Apr 15One Analyst Just Shaved Their ArcticZymes Technologies ASA (OB:AZT) Forecasts Dramatically
Jan 13Shareholder Returns
| AZT | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -1.8% | 0.4% | 1.3% |
| 1Y | -31.8% | -50.0% | -1.1% |
Return vs Industry: AZT exceeded the Norwegian Biotechs industry which returned -50% over the past year.
Return vs Market: AZT underperformed the Norwegian Market which returned -1.1% over the past year.
Price Volatility
| AZT volatility | |
|---|---|
| AZT Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in NO Market | 12.7% |
| 10% least volatile stocks in NO Market | 3.6% |
Stable Share Price: AZT's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: AZT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 53 | Michael Akoh | www.arcticzymes.com |
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It serves the molecular tools research and diagnostics, and biomanufacturing markets.
ArcticZymes Technologies ASA Fundamentals Summary
| AZT fundamental statistics | |
|---|---|
| Market cap | NOK 771.18m |
| Earnings (TTM) | NOK 1.29m |
| Revenue (TTM) | NOK 102.97m |
643.3x
P/E Ratio8.1x
P/S RatioIs AZT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZT income statement (TTM) | |
|---|---|
| Revenue | NOK 102.97m |
| Cost of Revenue | NOK 5.54m |
| Gross Profit | NOK 97.44m |
| Other Expenses | NOK 96.14m |
| Earnings | NOK 1.29m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 14, 2025
| Earnings per share (EPS) | 0.025 |
| Gross Margin | 94.62% |
| Net Profit Margin | 1.26% |
| Debt/Equity Ratio | 0% |
How did AZT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 22:17 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ArcticZymes Technologies ASA is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hans Bohn | Beringer Finance AB |
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |
| Espen Jørgensen | DNB Markets |